Iradimed Revenue Growth Rates (IRMD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Iradimed Corporation  (NASDAQ: IRMD)
 

IRMD's Revenue Growth by Quarter and Year

Iradimed's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IRMD/growth
https://api.csimarket.com/api/v1/companies/IRMD/fundamentals
https://api.csimarket.com/api/v1/companies/IRMD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IRMD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.20
2nd Quarter June 20.47
1st Quarter March 21.98
FY 66.65

IRMDs Annual Revenue
Iradimed's Revenue in the fiscal year 2025 $ 83.81 millions
Iradimed's Revenue in the fiscal year 2024 $ 73.24 millions
Iradimed's Revenue in the fiscal year 2023 $ 65.56 millions
Iradimed's Revenue in the fiscal year 2022 $ 53.30 millions
Iradimed's Revenue in the fiscal year 2021 $ 41.81 millions




IRMD Revenue third quarter 2026 Y/Y Growth Comment
Iradimed Corporation reported Revenue increase of 14.17% year on year in the third quarter 2026, to $ 24.20 millions, this is lower than Iradimed Corporation's recent average Revenue increase of 19.91%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 130 other companies have achieved higher Revenue growth. While Iradimed Corporation' s Revenue growth of 14.17% ranks overall at the positon no. 2752 in the third quarter 2026.


IRMD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 14.17 %
2nd Quarter June 0.29 %
1st Quarter March 12.66 %
FY   -

Financial Statements
Iradimed's third quarter 2026 Revenue $ 24.20 millions IRMD's Income Statement
Iradimed's third quarter 2025 Revenue $ 21.20 millions Quarterly IRMD's Income Statement


IRMD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.24 %
2nd Quarter June -6.87 %
1st Quarter March -3.13 %
FY (Year on Year)   -


Back to IRMD Growth rate Comparisons >> Back to IRMD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #131
Healthcare Sector #388
Overall #2752

Revenue Y/Y Growth Statistics
High Average Low
114.95 % 19.91 % -44.02 %
(Mar 31 2022)   (Sep 30 2017)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #131
Healthcare Sector #388
Overall #2752
Revenue Y/Y Growth Statistics
High Average Low
114.95 % 19.91 % -44.02 %
(Mar 31 2022)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Iradimed's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
145.4 % 4.71 % -41.54 %
(Dec 31 2013)  


IRMD's III. Quarter Q/Q Revenue Comment
Iradimed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue jump of 18.24%, to $ 24.20 millions, from $20.47 millions in the second quarter.
IRMD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 100 other companies have achieved higher Revenue quarter on quarter growth. While Iradimed's Revenue growth quarter on quarter, overall rank is 2656.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #101
Healthcare Sector #329
Overall #2656
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #101
Healthcare Sector #329
Overall #2656
Revenue Q/Q Growth Statistics
High Average Low
145.4 % 4.71 % -41.54 %
(Dec 31 2013)  


IRMD's III. Quarter Q/Q Revenue Comment
Iradimed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue jump of 18.24%, to $ 24.20 millions, from $20.47 millions in the second quarter.
IRMD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 100 other companies have achieved higher Revenue quarter on quarter growth. While Iradimed's Revenue growth quarter on quarter, overall rank is 2656.


Iradimed's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 89.34
Y / Y Revenue Growth (TTM) 10.97 %
Year on Year Revenue Growth Overall Ranking # 1336
Seqeuential Revenue Change (TTM) 3.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 2274


Cumulative Revenue growth Comment
Assuming the Iradimed's fiscal year would have ended in Sep 30 2026, Iradimed would have reprted above average annual Revenue increase of 10.97% year on year, of $ 89 millions.
This marks a slow-down of the companys growth trends and from the 11.21% rise in Jun 30 2026.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 625 to 1336.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 123
Healthcare Sector # 229
Overall # 1336

Revenue TTM Y/Y Growth Statistics
High Average Low
39.17 %
 1.16 %
-160.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 330
S&P 500 # 2274
Cumulative Revenue growth Comment
Assuming the Iradimed's fiscal year would have ended in Sep 30 2026, Iradimed would have reprted above average annual Revenue increase of 10.97% year on year, of $ 89 millions.
This marks a slow-down of the companys growth trends and from the 11.21% rise in Jun 30 2026.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 625 to 1336.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 123
Healthcare Sector # 229
Overall # 1336

Revenue TTM Y/Y Growth Statistics
High Average Low
39.17 %
1.16 %
-160.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 330
S&P 500 # 2274




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IRMD's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions


About Iradimed Revenue Growth Rates (IRMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Iradimed Corp (CIK 1325618).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-068576
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Iradimed Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.